M Ando

Tokyo University of Science, Edo, Tōkyō, Japan

Are you M Ando?

Claim your profile

Publications (361)1028.68 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tomosynthesis (TS) is a pseudo-3-dimensional image reconstruction method to recover depth-resolved information using restricted number of projections. In this research, refraction index based TS imaging using dark-field imaging (DFI) optics is proposed and biomedical soft tissues were imaged in low dose exposure. By a single exposure of an object, two projected images are obtained from a Laue-case analyzer of DFI. Calculating the both images refraction component is deduced, while two exposures are needed in DEI (diffraction enhanced imaging). Thus the measurement time and the radiation dose in DFI are half of DEI. In addition, the proposed reconstruction algorithm, derived from the quantitative relationship in measurement process, allows high contrast tomographic imaging in spite of one order smaller number of projections for CT (computed tomography). To demonstrate the proposed imaging protocol efficacy, an ex-vivo excised tissue of human lung were imaged using a system constructed at the vertical wiggler beamline at PF-BL14C at KEK. TS image is successfully delineated high quality soft tissue structures comparable to CT.
    Journal of Physics Conference Series 03/2013; 425(19):192012. DOI:10.1088/1742-6596/425/19/192012
  • [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundA phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC).Patients and methodsA total of 564 patients were randomly assigned to receive either carboplatin on day 1 plus oral S-1 on days 1-14 or carboplatin-paclitaxel on day 1 every 21 days. Updated results and post hoc subgroup analysis according to tumor histology are presented.ResultsThe updated analysis revealed a median OS of 15.2 months in the carboplatin-S-1 arm and 13.1 months in the carboplatin-paclitaxel arm, with a hazard ratio (HR) of 0.956 [95% confidence interval (CI) 0.793-1.151], consistent with the previous primary analysis. Median OS was 14.0 months in the carboplatin-S-1 arm and 10.6 months in the carboplatin-paclitaxel arm (HR 0.713; 95% CI 0.476-1.068) for patients with squamous cell carcinoma (SCC), with corresponding values of 15.5 and 13.9 months (HR 1.060; 95% CI 0.859-1.308) for those with non-SCC.Conclusions These results establish the efficacy and safety of carboplatin-S-1 in patients with advanced NSCLC regardless of tumor histology.
    Annals of Oncology 12/2012; 24(5). DOI:10.1093/annonc/mds629 · 6.58 Impact Factor
  • European Journal of Cancer 09/2011; 47. DOI:10.1016/S0959-8049(11)72441-8 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to compare thin-section CT images from sarcoidosis patients who had either normal or elevated serum KL-6 levels. 101 patients with sarcoidosis who underwent thin-section CT examinations of the chest and serum KL-6 measurements between December 2003 and November 2008 were retrospectively identified. The study group comprised 75 sarcoidosis patients (23 male, 52 female; aged 19-82 years, mean 54.1 years) with normal KL-6 levels (152-499 U ml(-1), mean 305.7 U ml(-1)) and 26 sarcoidosis patients (7 male, 19 female; aged 19-75 years, mean 54.3 years) with elevated KL-6 levels (541-2940 U ml(-1), mean 802.4 U ml(-1)). Two chest radiologists, unaware of KL-6 levels, retrospectively and independently interpreted CT images for parenchymal abnormalities, enlarged lymph nodes and pleural effusion. CT findings in sarcoidosis patients consisted mainly of lymph node enlargement (70/75 with normal KL-6 levels and 21/26 with elevated KL-6 levels), followed by nodules (50 and 25 with normal and elevated levels, respectively) and bronchial wall thickening (25 and 21 with normal and elevated levels, respectively). Ground-glass opacity, nodules, interlobular septal thickening, traction bronchiectasis, architectural distortion and bronchial wall thickening were significantly more frequent in patients with elevated KL-6 levels than those with normal levels (p<0.001, p<0.005, p<0.001, p<0.001, p<0.001 and p<0.001, respectively). By comparison, there was no significant difference in frequency of lymph node enlargement between the two groups. These results suggest that serum KL-6 levels may be a useful marker for indicating the severity of parenchymal sarcoidosis.
    The British journal of radiology 11/2010; 84(999):229-35. DOI:10.1259/bjr/65287605 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although characteristics of intraepithelial lymphocytes (IELs) in mucosal immunity have been well defined in the intestine, bronchial IELs have been little investigated. Recently, we showed that bronchial IELs have a distinct function that partly resembles that of intestinal IELs; however, surface antigen expression of bronchial IELs and the relationship of that expression to airway disease have not been studied. We analyzed phenotypic profiles of human bronchial IELs and lamina propria lymphocytes (LPLs) by double-staining immunohistochemistry using full-thickness bronchial specimens (10 nonasthmatic controls and 7 asthmatics) from lung resections. In controls, the percentage of CD4+ cells was lower, and the percentage of CD8+ cells was higher in IELs compared to LPLs (CD4: median 50.0% in IELs vs. 65.9% in LPLs, p = 0.01; CD8: 50.9% in IELs vs. 34.4% in LPLs, p = 0.007). The percentage of cells positive for CD103 (αE-integrin) was higher in IELs than that in LPLs (median 60.1% in IELs vs. 16.9% in LPLs; p < 0.001). In IELs from asthmatics, these characteristics were particularly significant (CD4: median 26.2%, p = 0.008; CD8: 79.8%, p = 0.007; CD103: 76.2%, p = 0.019; all compared with IELs from nonasthmatics). These results suggest that human bronchial IELs have roles distinct from subsets of other lymphocytes, and that CD8+ cells and CD103+ cells have potentially important functions in the bronchial epithelium.
    International Archives of Allergy and Immunology 01/2010; 153(2):157-65. DOI:10.1159/000312633 · 2.43 Impact Factor
  • American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California; 04/2009
  • American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California; 04/2009
  • American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California; 04/2009
  • American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California; 04/2009
  • [Show abstract] [Hide abstract]
    ABSTRACT: This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated non-small-cell lung cancer (NSCLC). Eligibility included pathologically or cytologically proven NSCLC, failure of one platinum-based regimen, performance status of zero or one, 20-75 years old, and adequate organ function. Patients received docetaxel 60 mg/m(2) (day 1) or docetaxel 60 mg/m(2) (day 8) and gemcitabine 800 mg/m(2) (days 1 and 8), both administered every 21 days until disease progression. Sixty-five patients participated in each arm. This trial was terminated early due to an unexpected high incidence of interstitial lung disease (ILD) and three treatment-related deaths due to ILD in the combination arm. Docetaxel plus gemcitabine compared with docetaxel-alone patients experienced similar grade and incidence of toxicity, except for ILD. No baseline factor was identified for predicting ILD. Median survival times were 10.3 and 10.1 months (one-sided P = 0.36) for docetaxel plus gemcitabine and docetaxel arms, respectively. Docetaxel alone is still the standard second-line treatment for NSCLC. The incidence of ILD is higher for docetaxel combined with gemcitabine than for docetaxel alone in patients with previously treated NSCLC.
    Annals of Oncology 02/2009; 20(5):835-41. DOI:10.1093/annonc/mdn705 · 6.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing rate of breast cancer in Japan is enormous in these years. Nevertheless only 2-3 % of female may receive mammography. In order to improve this number for early detection of breast cancer we have started development of a refraction-based visualization of breast cancer. This system comprises two types of imaging: one is for a regular annual or biyearly check of the breast cancer. This is a 2-D mode x-ray dark-field imaging where a Laue transmission type of angle analyzer with thickness of 2.124 mm is used for the FOV of 90 mm × 90 mm that can provide the spatial resolution better than 50 microns; the other a 3-D reconstruction for further detailed check to specify type and location of breast cancer.
    03/2007; 902(1). DOI:10.1063/1.2723617
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently we have developed a new Computed Tomography (CT) algorithm for refraction contrast that uses the optics of diffraction-enhanced imaging. We applied this new method to visualize soft tissue which is not visualized by the current absorption based contrast. The meaning of the contrast that appears in refraction-contrast X-ray CT images must be clarified from a biologic or anatomic point of view. It has been reported that the contrast is made with the specific gravity map with a range of approximately 10 muarc sec. However, the relationship between the contrast and biologic or anatomic findings has not been investigated, to our knowledge. We compared refraction-contrast X-ray CT images with microscopic X-ray images, and we evaluated refractive indexes of pathologic lesions on phase-contrast X-ray CT images. We focused our attenuation of breast cancer and lung cancer as samples. X-ray refraction based Computed Tomography was appeared to be a pathological ability to depict the boundary between cancer nest and normal tissue, and inner structure of the disease.
    AIP Conference Proceedings 01/2007; DOI:10.1063/1.2436463
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical program of intravenous coronary angiography (IVCAG) using synchrotron radiation is moving on at the ESRF and at the KEK. Since the X-ray optics and types of detectors are different depending on the needs of technology, the ESRF adopts dual-energy digital subtraction system and the KEK does single-energy two-dimensional dynamic imaging system. A contrast agent is injected intravenously and the image sequence is started. The former technique enhances the image contrast of the coronary arteries in spite of intravenous injection of a contrast agent; whereas, the latter technique produces excellent temporal resolution for imaging of moving objects such as the coronary arteries and the left ventricle. So, the obtained image, the radiation dose, the examination time, and other details are different between the two facilities. Both systems sufficiently visualize the right coronary artery disease, even after coronary angioplasty or coronary artery bypass grafting. Also, the two-dimensional dynamic IVCAG permits the visualization of the left coronary arteries. The coronary morphology obtained by the IVCAG, was almost completely coincident with the results of selective CAG. Accordingly, the IVCAG is clinically validated and useful for the screening and the follow-up of coronary artery disease. However, as some portions of the left circumflex coronary artery are overlapped by the left ventricle, more contrivance is required and its imaging should be improved in future.
    Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment 08/2005; 548(1):78-83. DOI:10.1016/j.nima.2005.03.070 · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper reports, the application of synchrotron radiation to basic medicine at SPring-8 involving instrumentation and medical application of imaging and scattering. Emphasis should be laid on X-ray dark-field imaging (DFI) whose goal is clinical diagnosis of organs that have been invisible by ordinary techniques. Development of this technique is under way both at SPring-8 and KEK. The X-ray optics of DFI comprises a Bragg asymmetric monochro-collimator and a Laue case analyzer with a diffraction index of 4 4 0 using the X-ray energy of 35 keV () in a parallel position. This analyzer that can provide with 80 mm×80 mm view size has 2.15 mm thickness. At present the spatial resolution is around 5–10 μm. Visibility of some organs such as soft bone tissue at excised human femoral head and breast cancer tissue is under test. This preliminary test shows that the DFI seems feasible in clinical diagnosis. Furthermore, a perspective view of application of synchrotron radiation to clinical medicine in Japan will be given.
    Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment 08/2005; DOI:10.1016/j.nima.2005.03.059 · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angular dependence of visibility at articular cartilage of an intact human finger and knee by X-ray dark-field imaging (DFI) and bright-field imaging (BFI) was tested. These specimens were fixed by formalin. Good contrast of the articular cartilage has been obtained, as a preliminary result, not only by DFI but also by pseudo-DFI and BFI around the just Bragg angle of the angular analyzing crystal. This may indicate that it is useful for clinical purpose to use both DFI and BFI not only at just Bragg angle but also around it.
    Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment 08/2005; 548:129-134. DOI:10.1016/j.nima.2005.03.079 · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the usefulness of double-dose (0.2 mmol/kg of gadoteridol) contrast-enhanced magnetic resonance imaging (C-E MRI) in detecting brain metastases of lung cancer. We prospectively enrolled 134 patients with lung cancer who had no neurologic symptoms and who underwent a staging work-up. Patients were assigned to receive both contrast-enhanced computerized tomography (C-E CT) and double-dose C-E MRI. Double-dose C-E MRI detected brain metastases in 19 patients, while C-E CT detected brain metastasis in only 12 of the 19 (P = 0.02). The 3-month survival rate for patients in double-dose C-E MRI group was found to be 2.06 times that of patients in a C-E CT group (P = 0.029), although the survival rate fell to 1.45 (P = 0.387) at 6 months. The results imply that double-dose C-E MRI changed the clinical stage of lung cancer patients. We concluded that double-dose C-E MRI improves the rate of detection of brain metastases during the initial staging of lung cancer.
    Lung Cancer 01/2005; 46(3):357-60. DOI:10.1016/j.lungcan.2004.05.011 · 3.74 Impact Factor
  • EJC Supplements 09/2003; 1(5). DOI:10.1016/S1359-6349(03)90091-7 · 9.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: T cells play an important role in the pathogenesis of bronchial asthma. However, it is not completely known how circulating lymphocytes infiltrate into the airways of asthmatic patients. Because SCID mice are unable to reject xenogenic transplants, many xenotransplant models using various human tissues have been developed. Therefore, to examine the interaction between bronchi and T lymphocytes of asthma, it may be possible to use the human bronchial xenograft and PBMC xenograft in SCID mice. We transplanted human bronchi into the subcutaneum of SCID mice and i.p. injected PBMCs that were obtained from patients with atopic asthma, atopic dermatitis and rheumatoid arthritis, and normal subjects (asthmatic, dermatitis, rheumatic, and normal huPBMC-SCID mice). There was no difference in the percentage of CD3-, CD4-, CD8-, CD25-, CD45RO-, CD103-, and cutaneous lymphocyte Ag-positive cells in PBMCs among the patients with asthma, dermatitis, rheumatoid arthritis, and normal subjects, and CD3-positive cells in peripheral blood of asthmatic, dermatitis, rheumatic, and normal huPBMC-SCID mice. The number of CD3-, CD4-, and CD8-positive cells in the xenografts of asthmatic huPBMC-SCID mice was higher than those of dermatitis, rheumatic, and normal huPBMC-SCID mice. IL-4 mRNA and IL-5 mRNA were significantly higher in the xenografts of asthmatic huPBMC-SCID mice than those in the xenografts of normal huPBMC-SCID mice, but there were no significant differences in the expressions of IL-2 mRNA or IFN-gamma mRNA between them. These findings suggest that T cells, especially Th2-type T cells, of asthmatics preferentially infiltrate into the human bronchi.
    The Journal of Immunology 07/2003; 170(11):5712-8. DOI:10.4049/jimmunol.170.11.5712 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study whether NRAMP1 gene polymorphisms in a Japanese population affect susceptibility to tuberculosis and clinical features of tuberculosis. Polymerase chain reaction and restriction fragment-length polymorphism analyses were used to type NRAMP1 polymorphisms in 95 patients with pulmonary tuberculosis and 90 controls. Clinical features of patients also were investigated. No association was seen between susceptibility to tuberculosis and NRAMP1 polymorphisms. Patients with the D543N A allele were significantly more likely than others to develop a cavitary lesion; by logistic regression analysis with adjustment for gender, age, and presence of diabetes, the odds ratio in patients with an A allele was 5.16 (95% confidence interval, 1.30-20.45). Genetic variation in the human NRAMP1 gene may be associated with cavitation in patients with tuberculosis.
    Journal of Infection 06/2003; 46(4):215-20. DOI:10.1053/jinf.2002.1064 · 4.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since R€ o ontgenÕs discovery of X-rays just over a century ago the vast majority of radiographs have been collected and interpreted on the basis of absorption contrast and geometrical (ray) optics. Recently the possibility of obtaining new and complementary information in X-ray images by utilizing phase-contrast effects has received considerable attention, both in the laboratory context and at synchrotron sources (where much of this activity is a consequence of the highly coherent X-ray beams which can be produced). Phase-contrast X-ray imaging is capable of providing improved in-formation from weakly absorbing features in a sample, together with improved edge definition. Four different exper-imental arrangements for achieving phase contrast in the hard X-ray regime, for the purpose of non-destructive characterization of materials, will be described. Two of these, demonstrated at ESRF in France and AR in Japan, are based on parallel-beam geometry; the other two, demonstrated at PLS in Korea and APS in USA, are based on spherical-beam geometry. In each case quite different X-ray optical arrangements were used. Some image simulations will be employed to demonstrate salient features of hard X-ray phase-contrast imaging and examples of results from each of the experiments will be shown.
    Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms 01/2003; 199:427-435. DOI:10.1016/S0168-583X(02)01557-4 · 1.19 Impact Factor

Publication Stats

5k Citations
1,028.68 Total Impact Points

Institutions

  • 2007–2013
    • Tokyo University of Science
      • Research Institute for Science and Technology
      Edo, Tōkyō, Japan
  • 1996–2012
    • Nagoya University
      • Division of of Internal Medicine
      Nagoya, Aichi, Japan
    • Kumamoto Municipal Citizens Hospital
      Kumamoto, Kumamoto Prefecture, Japan
  • 2011
    • Kyoto University
      Kioto, Kyōto, Japan
  • 1994–2010
    • Oita University
      • • Faculty of Medicine
      • • Third Department of Internal Medicine
      Ōita, Ōita, Japan
  • 1995–2005
    • The Graduate University for Advanced Studies
      • Department of Materials Structure Science
      Miura, Kanagawa-ken, Japan
  • 1989–2005
    • High Energy Accelerator Research Organization
      • • Institute of Materials Structure Science
      • • Photon Factory
      Tsukuba, Ibaraki, Japan
  • 1988–2002
    • Kumamoto University
      • • Department of Obstetrics and Gynecology
      • • Department of Medical Biochemistry
      Kumamoto, Kumamoto, Japan
  • 2001
    • Japanese Red Cross
      Edo, Tōkyō, Japan
  • 1999
    • Umeå University
      • Department of Medical Biochemistry and Biophysics
      Umeå, Vaesterbotten, Sweden
  • 1997–1999
    • University of Tsukuba
      • Institute of Clinical Medicine
      Tsukuba, Ibaraki-ken, Japan
    • First Solar
      Tempe, Arizona, United States
    • The University of Tokyo
      • Department of Applied Physics
      Tokyo, Tokyo-to, Japan
  • 1994–1997
    • Osaka University
      • Department of Radiology
      Ōsaka-shi, Osaka-fu, Japan
  • 1990
    • Tokyo Metropolitan University
      • Department of Physics
      Edo, Tōkyō, Japan
  • 1987–1988
    • Fujita Health University
      • Department of Physiology
      Nagoya, Aichi, Japan